NASDAQ:KYNB Kyntra Bio 5/11/2026 Earnings Report $7.05 +0.25 (+3.66%) As of 02:50 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Kyntra Bio EPS ResultsActual EPS-$3.74Consensus EPS -$3.36Beat/MissMissed by -$0.38One Year Ago EPSN/AKyntra Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKyntra Bio Announcement DetailsQuarterDate5/11/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Kyntra Bio Earnings HeadlinesKyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call TranscriptMay 11 at 10:01 PM | seekingalpha.comKyntra Bio to Report First Quarter 2026 Financial ResultsMay 4, 2026 | globenewswire.comBSEM: From OTC to Nasdaq Contender!BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited financials for 2024 and 2025 - a key step toward its Nasdaq uplisting. The company paired that move with a $40 million acquisition expanding its reach into hospitals and surgical centers, all within a $300M-plus addressable market. Zacks carries a $25.50 price target on the stock.May 12 at 1:00 AM | Huge Alerts (Ad)Contrasting Acerus Pharmaceuticals (OTCMKTS:ASPCF) & Kyntra Bio (NASDAQ:KYNB)May 3, 2026 | americanbankingnews.comKyntra Bio to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | globenewswire.comKyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call TranscriptMarch 16, 2026 | seekingalpha.comSee More Kyntra Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kyntra Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyntra Bio and other key companies, straight to your email. Email Address About Kyntra BioFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.View Kyntra Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?On Holdings Sets Up for Marathon Rally: New Highs Are ComingShake Shack Stock Gets Shaken After Earnings MissRocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?Axon Surged After Earnings and Is Still Down Over 50% From HighsMP Materials Is Quietly Building a Rare Earth PowerhouseAST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival? Upcoming Earnings Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026)Applied Materials (5/14/2026)Brookfield (5/14/2026)National Grid Transco (5/14/2026)NU (5/14/2026)Mizuho Financial Group (5/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
